Lipocine is trading 11.33% down at $1.95, with no confirmed company-specific catalyst identified for the October 8 decline.
- The latest company announcement was October 7, when Health Canada approved TLANDO through licensing partner Verity, which plans a Canadian launch by year-end. That prior approval does not establish the reason for the decline.
- The broader market is softer, but provided major-index moves show no same-direction decline greater than 0.5% that clearly explains Lipocine’s move.